All are natural leaders, and they share the same gender and title. But each has taken a different path to Silicon Valley success in the growing healthtech sector, with its own twists and trials.
Their stories, however, in an era marked by angst in executive suites and VC conference rooms over gender equity and harassment-related issues, reveal patterns in a larger tapestry. And perhaps glimpses of a few paths to progress.
Leslie Trigg, CEO of 110-employee Outset Medical in San Jose— which has raised $190 million and won FDA clearance for a revolutionary new dialysis treatment platform — credits three male mentors for helping her on the path that led to those accomplishments.
But before that, she took her new MBA from UC Berkeley’s Haas School of Business and applied to virtually every biotechnology company around.
“I got rejected by every biotech company,” Trigg says, “because I was essentially competing against people who had an MBA but (also) had an undergraduate science degree,” which she didn’t have.
Read More: https://www.bizjournals.com/sanjose/news/2018/05/31/women-of-healthtech-these-4-ceos-want-to-change.html?b=1527776492%5E21269447
Via: Omada Health Digital Therapeutics Pioneer Becomes Largest Diabetes Prevention Program Provider to Achieve Milestone Via: Cision PRWeb New study shows Hinge Health wearable sensors and coaching significantly improves chronic knee pain without opioids or surgery Via: Seeking Alpha Summary: Via: Fortune Omada Health pulled off something that was, especially at the time, highly unusual in the ever-burgeoning yet still-fledgling digital health space: In 2016, the company scored federal government reimbursements for its diabetes prevention program. It’s continued to grow since then and shared results from nine different peer-reviewed studies noting significant results for diabetes, cardiovascular disease, and obesity patients—a case study in how at least one company in the sphere is using data to try and fuel real world patient outcomes. Via: OncoMed REDWOOD CITY, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that five posters will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 14-18, 2018, in Chicago. Among the presentations will be preclinical data for OncoMed's novel anti-TIGIT (OMP-313M32) immuno-oncology program, which is currently in a Phase 1a single-agent clinical study. Preclinical data for OncoMed's differentiated clinical-stage GITRL-Fc (OMP-336B11) program will also be featured. In addition, preclinical immuno-oncology data for OncoMed's Wnt antagonist vantictumab (anti-FZD, OMP-18R5) in combination with immune checkpoint inhibitors will be presented. Via: Cision PR Newswire Plan helps accounts choose the right solutions to keep employees healthy and lower health care costs Via: FOX17 News GRAND RAPIDS, Mich. -- There's a new life-saving procedure that's helping patients at Spectrum Health in Grand Rapids. Via: BusinessWire SUNNYVALE, Calif.--(BUSINESS WIRE)--Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced that medical device industry veteran Donald J. Zurbay has joined its board of directors. Via: Fortune Excerpt: |
Archives
October 2023
|